Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will announce its third quarter 2020 financial results on November 6, 2020, before market opening. A conference call will follow at 9:00 a.m. Pacific Time to discuss the results. Amphastar specializes in developing and marketing generic and proprietary injectable and inhalation products, primarily for hospital use. The company emphasizes its commitment to high-quality products with technical barriers and operates mainly through group purchasing organizations and wholesalers.
- Scheduled earnings announcement could provide insights into financial performance.
- Focus on developing products with high technical barriers suggests potential for strong market positioning.
- Uncertainty surrounding COVID-19's impact on operations and market demand.
RANCHO CUCAMONGA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2020 ended September 30, 2020, before the market opens on Friday, November 6th, 2020, and will hold a conference call to discuss its financial results at 9:00 a.m. Pacific Time.
To access the conference call, dial toll free (877) 881-2595, five minutes before the conference. The passcode for the conference call is 7086853.
The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.
Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. In particular, the extent of COVID-19’s impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change.
Contact:
William J. Peters
Chief Financial Officer
(909) 980-9484
FAQ
When will Amphastar Pharmaceuticals release its Q3 2020 earnings report?
What time is the conference call for Amphastar's Q3 2020 financial results?
How can I access the conference call for Amphastar's Q3 2020 results?
What is Amphastar Pharmaceuticals' primary business focus?
What potential risks does Amphastar mention in its press release?
